Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 248, Issue 1-2, Pages 40-47Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2011.11.004
Keywords
Multiple sclerosis; Biomarker; Technologies; Mass spectrometry; Proteomics; Cerebrospinal fluid
Categories
Funding
- Dutch Multiple Sclerosis Research Foundation
- UEPHA-MS [PITN-GA-2008-212877]
- EU
Ask authors/readers for more resources
Multiple sclerosis is a disabling inflammatory and neurodegenerative disorder that predominantly affects young adults. There is a great need for biomarkers, which could elucidate pathology as well as provide prognosis of disease progression and therapy response in multiple sclerosis. Rapidly evolving, technology driven applications such as mass spectrometry based proteomics are currently being developed for this purpose. In this review, we will outline the current status of the field and detail a number of the bottlenecks as well as future prospects of this type of biomarker research. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available